X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

0 Comments | | Return |

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

Sample submission during the national blood shortage

Through communications with our clients, CTS is aware of the current national blood shortage. We rea...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

Pooled Zika Testing and New CTS Website Functionality- November 29th Update

As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

National Blood Donor Month

National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...

Read More >

Subscribe here to receive CTS updates!

Name